Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors
- 13 June 2008
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 370 (4), 536-540
- https://doi.org/10.1016/j.bbrc.2008.03.066
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- BetaIg-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells.2007
- The Transforming Growth Factor-β-inducible Matrix Protein βig-h3 Interacts with FibronectinOnline Journal of Public Health Informatics, 2002
- Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.2002
- Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.2002
- DEC1 is a downstream target of TGF-β with sequence-specific transcriptional repressor activitiesProceedings of the National Academy of Sciences of the United States of America, 2002
- Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer.Japanese Journal of Clinical Oncology, 2002
- Secreted and cell surface genes expressed in benign and malignant colorectal tumors.2001
- von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.2001
- VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix SignalingMolecular and Cellular Biology, 2001
- Regulation of STRA13 by the von Hippel-Lindau Tumor Suppressor Protein, Hypoxia, and the UBC9/Ubiquitin Proteasome Degradation PathwayOnline Journal of Public Health Informatics, 2001